Tsuboi M - Search Results

1

Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer.

Sugiyama E, Togashi Y, Takeuchi Y, Shinya S, Tada Y, Kataoka K, Tane K, Sato E, Ishii G, Goto K, Shintani Y, Okumura M, Tsuboi M, Nishikawa H. Sugiyama E, et al. Among authors: tsuboi m. Sci Immunol. 2020 Jan 31;5(43):eaav3937. doi: 10.1126/sciimmunol.aav3937. Sci Immunol. 2020. PMID: 32005679

2

[Current status of adjuvant chemotherapy for the resected non-small cell lung cancer].

Tsuboi M, Kato H. Tsuboi M, et al. Nihon Rinsho. 2002 May;60 Suppl 5:329-34. Nihon Rinsho. 2002. PMID: 12101682 Review. Japanese. No abstract available.

3

[The application of extended resection for non-small cell lung cancer].

Tsuboi M, Harubumi K. Tsuboi M, et al. Nihon Geka Gakkai Zasshi. 2005 Jun;106(6):367-74. Nihon Geka Gakkai Zasshi. 2005. PMID: 15977578 Review. Japanese.

4

Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.

Tsuboi M, Le Chevalier T. Tsuboi M, et al. Med Oncol. 2006;23(2):161-70. doi: 10.1385/MO:23:2:161. Med Oncol. 2006. PMID: 16720916

5

Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.

Kosaka T, Yatabe Y, Endoh H, Yoshida K, Hida T, Tsuboi M, Tada H, Kuwano H, Mitsudomi T. Kosaka T, et al. Among authors: tsuboi m. Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714. Clin Cancer Res. 2006. PMID: 17020982

6

The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Tsuboi M, Ohira T, Saji H, Miyajima K, Kajiwara N, Uchida O, Usuda J, Kato H. Tsuboi M, et al. Ann Thorac Cardiovasc Surg. 2007 Apr;13(2):73-7. Ann Thorac Cardiovasc Surg. 2007. PMID: 17505412 Review.

7

[Lung cancer].

Tsuboi M, Kato H. Tsuboi M, et al. Gan To Kagaku Ryoho. 2007 Oct;34(10):1538-42. Gan To Kagaku Ryoho. 2007. PMID: 17940368 Review. Japanese.

8

Vinorelbine plus gemcitabine followed by docetaxel versus carboplatin plus paclitaxel in patients with advanced non-small-cell lung cancer: a randomised, open-label, phase III study.

Kubota K, Kawahara M, Ogawara M, Nishiwaki Y, Komuta K, Minato K, Fujita Y, Teramukai S, Fukushima M, Furuse K; Japan Multi-National Trial Organisation. Kubota K, et al. Lancet Oncol. 2008 Dec;9(12):1135-42. doi: 10.1016/S1470-2045(08)70261-4. Epub 2008 Nov 13. Lancet Oncol. 2008. PMID: 19013107 Clinical Trial.

9

Phase II study of erlotinib in Japanese patients with advanced non-small cell lung cancer.

Takahashi T, Yamamoto N, Nukiwa T, Mori K, Tsuboi M, Horai T, Masuda N, Eguchi K, Mitsudomi T, Yokota S, Segawa Y, Ichinose Y, Fukuoka M, Saijo N. Takahashi T, et al. Among authors: tsuboi m. Anticancer Res. 2010 Feb;30(2):557-63. Anticancer Res. 2010. PMID: 20332470 Clinical Trial.

10

Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.

Hishida T, Nagai K, Mitsudomi T, Yokoi K, Kondo H, Horinouchi H, Akiyama H, Nagayasu T, Tsuboi M; Japan Clinical Oncology Group. Hishida T, et al. Among authors: tsuboi m. J Thorac Cardiovasc Surg. 2010 Nov;140(5):e69-71. doi: 10.1016/j.jtcvs.2010.06.035. Epub 2010 Aug 2. J Thorac Cardiovasc Surg. 2010. PMID: 20674944 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

985 results

Search Page